(Reuters) - Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on ...

J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.

Affected Alaris products may have been serviced with previously recalled bezel kit assemblies. BD in 2019 recalled those kit ...

The global Hemostats Market, valued at US$2.80 billion in 2024 stood at US$2.90 billion in 2025 and is projected to advance at a resilient ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Johnson & Johnson stock jumped Wednesday after the Dow health behemoth raised its guidance in the wake of a bullish second-quarter report.